Shomron Ben-Horin

Shomron Ben-Horin (Hebrew: שומרון בן-חורין; born 1968, Tel Aviv) is an Israeli physician, a co-founder & Chief Medical Officer of Evinature, and professor of medicine at the Tel-Aviv University.

He received his MD from the Hadassah School of Medicine of the Hebrew University of Jerusalem before completing his gastroenterology training at Sheba Medical Center in Tel Aviv.

Medical career

Ben-Horin is the chief of the Gastroenterology Department at Sheba Medical Center, Israel. He was previously Director of the inflammatory bowel disease service at the Sheba Gastroenterology Department.

He was a postdoctoral scientist in the laboratory of human immunology at NewYork-Presbyterian Hospital, and in 2015, was an adjunct professor of medicine at the 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

After his successful trial on CurQD for patients with ulcerative colitis, Ben-Horin founded Evinature with his research partner, Nir Salomon in 2020.

Professional organizations

Ben-Horin is the president of the Israel IBD Society. He has served as associate editor of the Journal of Crohn's & Colitis (JCC) and is currently a member of the editorial board of Gut (journal) and the Scientific Committee of the European Crohn's & Colitis Organization (ECCO).

He has also served as a member of the steering committee of the Israeli Gastro Association and is the director of IBD Passport, a web-based global support program for traveling IBD patients.

Clinical and scientific fields of interest

Ben-Horin's main research focus is drug mechanisms, therapeutic drug monitoring and immunogenicity of biologics, response to biologic antibody drugs in IBD, and opportunistic infections in IBD. He has authored several hundred peer-reviewed articles, cited over 21,000 times, and served as the principal investigator and sub-investigator in over 20 clinical trials, notably two multi-center prospective randomized controlled trials: Comparison of steroids+5ASA versus steroids alone in acute severe UC (7 sites in Israel, Europe, China and Korea) and one placebo-controlled RCT of Curcumin as add-on therapy for mild-moderate active UC (Israel, Cyprus and Hong-Kong).

Selected publications

• Ben-Horin, Shomron; Farfel, Zvi; Mouallem, Meir (2002). "Gastroenteritis-Associated Hyperamylasemia". Archives of Internal Medicine. 162 (6): 689–692. doi:10.1001/archinte.162.6.689. PMID 11911723.
• Ben-Horin, Shomron; Bardan, Eytan; Barshack, Iris; Zaks, Nurit; Livneh, Avi (2003). "Cholesterol Crystal Embolization to the Digestive System: Characterization of a Common, Yet Overlooked Presentation of Atheroembolism". American Journal of Gastroenterology. 98 (7): 1471–1479. doi:10.1111/j.1572-0241.2003.07532.x. PMID 12873565.
• Ben-Horin, Shomron; Green, Peter H R.; Bank, Ilan; Chess, Leonard; Goldstein, Itamar (2006). "Characterizing the circulating, gliadin-specific CD4+ memory T cells in patients with celiac disease: Linkage between memory function, gut homing and Th1 polarization". Journal of Leukocyte Biology. 79 (4): 676–685. doi:10.1189/jlb.0705414. PMID 16415168.
• Ben-Horin, Shomron; Bar-Meir, Simon; Avidan, Benjamin (2007). "The Impact of Colon Cleanliness Assessment on Endoscopists' Recommendations for Follow-Up Colonoscopy". The American Journal of Gastroenterology. 102 (12): 2680–2685. doi:10.1111/j.1572-0241.2007.01486.x. PMID 17714555.
• Ben-Horin, Shomron; Bar-Meir, Simon; Avidan, Benjamin (2009). "The outcome of a second preparation for colonoscopy after preparation failure in the first procedure". Gastrointestinal Endoscopy. 69 (3): 626–630. doi:10.1016/j.gie.2008.08.027. PMID 19251002.
• Ben-Horin, S.; Goldstein, I.; Fudim, E.; Picard, O.; Yerushalmi, Z.; Barshack, I.; Bank, I.; Goldschmid, Y.; Meir, S Bar; Mayer, L.; Chowers, Y. (2009). "Early preservation of effector functions followed by eventual T cell memory depletion: A model for the delayed onset of the effect of thiopurines". Gut. 58 (3): 396–403. doi:10.1136/gut.2008.157339. PMID 18832521.
• Ben-Horin, S.; Margalit, M.; Bossuyt, P.; Maul, J.; Shapira, Y.; Bojic, D.; Chermesh, I.; Al-Rifai, A.; Schoepfer, A.; Bosani, M.; Allez, M.; Lakatos, P.L.; Bossa, F.; Eser, A.; Stefanelli, T.; Carbonnel, F.; Katsanos, K.; Checchin, D.; Sáenz De Miera, I.; Chowers, Y.; Moran, G.W. (2009). "P129 - the impact of concomitant treatment with immuno-modulators and antibiotics on the outcome of C. Difficile-associated inflammatory bowel disease exacerbation: An ECCO multi-center retrospective study". Journal of Crohn's and Colitis. 3: S62. doi:10.1016/S1873-9946(09)60156-2.
• Ben-Horin, S.; Yavzori, M.; Katz, L.; Kopylov, U.; Picard, O.; Fudim, E.; Coscas, D.; Bar-Meir, S.; Goldstein, I.; Chowers, Y. (2011). "The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful". Gut. 60: 41–48. doi:10.1136/gut.2009.201533. PMID 20519742.
• Ben-Horin, Shomron; Yavzori, Miri; Kopylov, Uri; Picard, Orit; Fudim, Ella; Eliakim, Rami; Chowers, Yehuda; Lang, Alon (2011). "Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease". Journal of Crohn's and Colitis. 5 (6): 555–558. doi:10.1016/j.crohns.2011.05.006. PMID 22115374.
• Ben-Horin, S.; Mazor, Y.; Yanai, H.; Ron, Y.; Kopylov, U.; Yavzori, M.; Picard, O.; Fudim, E.; Maor, Y.; Lahat, A.; Coscas, D.; Eliakim, R.; Dotan, I.; Chowers, Y. (2012). "The decline of anti-drug antibody titres after discontinuation of anti-TNFs: Implications for predicting re-induction outcome in IBD". Alimentary Pharmacology & Therapeutics. 35 (6): 714–722. doi:10.1111/j.1365-2036.2012.04997.x. PMID 22288419.
• Ben–Horin, Shomron; Bujanover, Yoram; Goldstein, Shulamit; Nadler, Moshe; Lang, Alon; Kopylov, Uri; Katz, Lior; Lahat, Adi; Schwartz, Eli; Avidan, Benjamin (2012). "Travel-Associated Health Risks for Patients with Inflammatory Bowel Disease". Clinical Gastroenterology and Hepatology. 10 (2): 160–165.e1. doi:10.1016/j.cgh.2011.10.025. PMID 22056299.